HIV PrEP Priming of Immune Effectors (PREPPIE)

HIV Pre-Exposure Prophylaxis Priming of Immune Effectors

Can HIV-specific immunity develop in HIV uninfected humans exposed to HIV whilst receiving antiretroviral pre-exposure prophylaxis (PrEP)? Investigators will investigate this possibility in commercial sex workers in Kampala who will be receiving Truvada PrEP for one year.

Study Overview

• Status: Unknown
• Conditions: HIV-1 Infections
• Intervention / Treatment: Drug: TDF/FTC

Detailed Description

Design This will be a single centre open label longitudinal observational trial. Women attending the "Good Health for Women" clinic will be informed about the objectives of the trial and volunteers able to provide informed consent and with high risk of exposure to HIV-1 determined by a sexual history questionnaire will be screened by Rapid antibody test. Seronegatives will be checked for eligibility by clinical examination and laboratory tests. The endpoint for enrolment will be 220 uninfected high risk participants.

Baseline blood samples will be obtained from participants at month 0. A monthly diary card will be provided for self documenting sexual exposure, alcohol use and pill taking. Participants will receive provisions of PrEP (tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) sufficient for one month, will be instructed on the daily prophylaxis and on how to record adherence on the diary card. Participants will be asked to return each month for treatment re-provisioning and a new card. The content of the diary card will be discussed in a short interview each month.

At month 6 and 12 blood samples will be collected for evaluating immune responses to HIV-1. Additional tests will be done for monitoring HIV-1 status, pregnancy and sexually transmitted infections (STIs). After month 12 PrEP will be discontinued (unless participants opt to continue PrEP until the end of the follow up) and all participants will provide blood samples at month 18.

Baseline and follow-up peripheral blood mononuclear cells (PBMC) samples will be compared for T cell responses to HIV by interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT). In case of a positive immune response, plasma collected at the same time point will be nucleic acid test (NAT) tested to verify absence of HIV infection.

HIV infected participants will be evaluated for cluster of differentiation 4 (CD4) T cells and viral load and referred to a Care Program (PEPFAR).

At month 6, 12 and 18 in-depth interviews will be conducted with a randomly selected sample of 44 women (20 percent) to discuss facilitators and barriers to adherence. The diary answers will be tabulated to look for patterns and trends. A framework approach to analysis will be used for the analysis of the qualitative data from interviews.

• Study Type: Interventional
• Enrollment (Anticipated): 220
• Phase: Phase 4

Contacts and Locations

Study Locations

• Uganda
  • Kampala, Uganda
    • Recruiting
    • MRC/UVRI Uganda Research Unit on Aids - Good Health for Women Project
    • Contact: Berna Kalanzi; Phone Number: 157 256417704000; Email: Berna.Kalanzi@mrcuganda.org
    • Contact: Afusa Nabuuma; Phone Number: 157 256417704000; Email: Afusa.Nabuuma@mrcuganda.org
    • Principal Investigator: Yunia Mayanja, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• age ≥18 at screening
• not intending to move away from the clinic's catchment area for the next 2 years
• HIV-1 antibody negative
• reports commercial sex work
• contact information is provided
• written informed consent

Exclusion Criteria:

• HIV infection at screening
• participation in previous or concurrent HIV vaccine trials
• lactating, pregnant or planning pregnancy
• renal function impairment (serum creatinine >1.5 mg/dl), Fanconi syndrome
• abnormal liver function tests (AST/ALT > 43 U/L), liver disease, viral hepatitis, hepatitis B virus (HBV) infection
• serum phosphorus <2.2mg/dl, osteoporosis
• known sensitivity to components of the Truvada® formulation
• any immunosuppressive treatment, such as systemic corticosteroids
• assumption of medication that interacts with Truvada®
• high likelihood of poor adherence to PREP and clinic attendance
• any condition that in the opinion of the attending physician could endanger the health of the participant or render her unsuitable to participate in the trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: TDF/FTC; All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.	Drug: TDF/FTC; All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.; Other Names: Truvada®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in IFN-γ ELISPOT response to HIV-1 peptides in persistently uninfected individuals between baseline and 12 months on PREP	0-12 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in IFN-γ ELISPOT response to HIV-1 peptides in persistently uninfected individuals between baseline and 6 months on PREP	0-6 months
Change in IFN-γ ELISPOT response to HIV-1 peptides in persistently uninfected individuals between 12 months on PREP and at 18 months after PREP cessation	12-18 months

Other Outcome Measures

Outcome Measure	Time Frame
HIV-1 incidence.	0-18 months
Viral load among participants who become infected with HIV-1 despite PREP.	0-18 months
Adherence to PREP as measured by plasma sampling.	0-18 months
Adherence to PREP as measured by pill counts.	0-18 months
Adherence to PREP as measured by participant self-report.	0-18 months

Collaborators and Investigators

• Sponsor: MRC/UVRI and LSHTM Uganda Research Unit
• Investigators: Principal Investigator: Pietro Pala, MD, MRC/UVRI and LSHTM Uganda Research Unit

Publications and helpful links

General Publications

• Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 2008 Aug 5;5(8):e157; discussion e157. doi: 10.1371/journal.pmed.0050157.

Study record dates

Study Major Dates

• Study Start (Actual): May 25, 2017
• Primary Completion (Anticipated): April 1, 2018
• Study Completion (Anticipated): June 1, 2018

Study Registration Dates

• First Submitted: October 21, 2015
• First Submitted That Met QC Criteria: October 30, 2015
• First Posted (Estimate): November 1, 2015

Study Record Updates

• Last Update Posted (Actual): September 19, 2017
• Last Update Submitted That Met QC Criteria: September 18, 2017
• Last Verified: September 1, 2017

More Information

Terms related to this study

• Keywords: HIV-1; immune response; pre-exposure prophylaxis (PrEP)
• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
• Other Study ID Numbers: PREPPIE001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes